Least Burdensome Additional-Info Requests? US FDA Needs Metrics, GAO Says
Executive Summary
The US Government Accountability Office says FDA needs more information to prove that is properly applying least-burdensome concepts for deficiency or additional-information letters sent to companies while reviewing pre-market submissions. FDA defends its performance, but plans to conduct more assessments.